Lenacapvir Demonstrates Small Margin of Resistance for Those Heavily Treated With HIV

Patients with HIV who were resistant to treatment with lenacapavir (Sunlenca; Gilead Sciences Inc) were found to have inadequate adherence to optimized background regimen or did not have a fully active antiretroviral.

Related Keywords

United Arab Emirates ,United States ,Japan ,Switzerland ,Australia ,Poland ,Israel ,Canada ,Warsaw ,L67 ,Jared Baeten ,Corona Borealis ,European Union ,Gilead Sciences Inc ,Clinical Development At Gilead Sciences ,Gilead Sciences ,United Kingdome ,